Clinical Trial Results:
Long-term follow-up: A long-term, open, follow-up of the immunogenicity and safety of the vaccine in healthy female subjects vaccinated either pre- or post-menarche in the HPV-012 study. Primary: A phase III, double-blind, randomized study to assess the consistency of the immunogenicity of three consecutive production lots of GlaxoSmithKline Biologicals’ HPV-16/18 VLP/AS04 vaccine administered intramuscularly according to a 0, 1, 6-month schedule in healthy female subjects aged 10 – 25 years.
Due to the EudraCT – Results system being out of service between 31 July 2015 and 12 January 2016, these results have been published in compliance with revised timelines
Summary
|
|
EudraCT number |
2004-001173-26 |
Trial protocol |
DK FI |
Global completion date |
06 Jan 2009
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
27 Aug 2016
|
First version publication date |
27 Aug 2016
|
Other versions |
|
Summary report(s) |
580299-012-Clinical-Study-Result-Summary |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.